Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma-Reference-Cited by-同舟云学术

Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma

Published:2018-11-03 Issue:3 Volume:57 Page:195-203
ISSN:0021-9665
Container-title:Journal of Chromatographic Science
language:en
Short-container-title:

Author:

Nassar Ala F¹²,Wisnewski Adam V¹,Wu Terence³,Lam Tukiet T⁴,King Ivan⁵

Affiliation:

1. Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA

2. Department of Chemistry, 55 N. Eagleville Rd., University of Connecticut, Storrs, CT, USA

3. West Campus Analytical Core, Yale University, West Haven, CT, USA

4. Department of Molecular Biophysics and Biochemistry, Yale-Keck MS and Proteomics Resource, Yale University, New Haven, CT, USA

5. Metastagen, Inc., Wilmington, DE, USA

Funder

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health

Publisher

Oxford University Press (OUP)

Subject

General Medicine,Analytical Chemistry

Link

http://academic.oup.com/chromsci/article-pdf/57/3/195/27696537/bmy100.pdf

Reference26 articles.

1. Cancer chemotherapy—the first twenty-five years;Scott;BMJ (Clinical Research ed.),1970

2. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders;Goodman;JAMA : the Journal of the American Medical Association,1946

3. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma;Wiedemann;European Journal of Cancer,1996

4. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas;Penketh;Biochemical Pharmacology,2000